adcetris
Commercial- Indications
- Hodgkin lymphoma, Large cell lymphoma
Company intelligence / Profile preview
Seagen Inc.
Bothell, Washington, United Statespfizer.com ↗
- Ownership
- Public · SGEN
- Employees
- ~2500
- Development stage
- Commercial
01
Overview
Seagen has four FDA-approved products—Adcetris, Padcev, Tukysa, and Tivdak—across hematologic malignancies and solid tumors. Adcetris alone has annual sales exceeding $1 billion and is approved for six blood cancer types. The company’s pipeline includes additional ADCs and immuno-oncology agents in various clinical stages
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugates (ADCs)Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Takeda Pharmaceutical Company – co-development/commercialization of Adcetris outside US/CanadaAstellas Pharma – co-development of PadcevGenmab – co-development of TivdakMerck & Co. – collaboration on ladiratuzumab vedotin with $1B equity investment in September 2020
04
Financials
- Market cap
- $43.2B
- Total revenue
- $648.7M
- Enterprise value
- $42B
Beyond the preview
Go deeper on Seagen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seagen Inc..